FHFeihuang Han

Feihuang Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Feihuang Han has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Dunliang Ma

    Department of Cardiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

    5 shared publications
  • Qiheng Wan

    Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, 510080, China

    4 shared publications
  • Yuqing Huang

    Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences Guangzhou Guangdong China

    4 shared publications
  • Zehan Huang

    Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou 510080, China

    4 shared publications
  • Bin Zhang

    Department of Cardiology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, 510080 Guangzhou, Guangdong, China

    3 shared publications
  • Bin Zhang

    Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, P.R. China

    3 shared publications

Latest Publications

  • Retrograde‐Guided Antegrade Puncture Reentry Technique for Retrograde CTO PCI: Procedural Outcome and Safety Evaluation

    by Zehan Huang, QiHeng Wan, YaoJun Zhang, FeiHuang Han, DunLiang Ma, Wang Feng, Yuqing Huang, LiTian Lin, Bin Zhang

    Background: Improving the efficiency of traversing the occluded segment is important in retrograde chronic total occlusion (CTO) percutaneous coronary intervention (PCI). We developed the retrograde‐guided antegrade puncture reentry (RPR) technique to improve procedural efficiency while maintaining safety in retrograde CTO PCI. Methods: This retrospective study included 336 patients who underwent retrograde CTO PCI between July 2024 and August 2025. Patients were categorized into the RPR group, the Non‐RPR group, and the Directly Crossing group. The primary outcome was CTO crossing time, defined as the interval from retrograde guidewire crossing of the collateral channel to wire externalization or wiring crossing into distal true lumen. Subgroup analyses were performed within the RPR cohort, and multivariate logistic regression was used to identify predictors of RPR success. Results: Despite higher lesion complexity in the RPR group, CTO crossing time was significantly shorter with RPR than with Non‐RPR strategies (13 [6–24.75] min vs. 25 [15–43] min; p < 0.001). Primary RPR achieved successful reentry in 67% of cases and demonstrated the shortest crossing time among all strategies. Failed RPR did not prolong subsequent bailout R‐CART. Complications were infrequent, including a 2.3% perforation rate, and no in‐hospital mortality in the RPR group. Calcification and occlusion length were independent predictors of RPR failure, whereas prior CTO PCI was associated with higher likelihood of RPR success. Conclusions: RPR is a safe and efficient adjunct to retrograde CTO PCI and may serve as an effective initial reentry strategy in selected cases.

  • Open Access

    Intentional Intimal Tracking Via a 6-F Guiding Catheter Using a Novel Puncture Wire

    by Hang Liu, Dunliang Ma, Zehan Huang, Feihuang Han, Zhaozhe Chen, Xiangdong Sun, Jun Yang, Chenhui Xiong, Liguo Jian, Bin Zhang

  • Open Access

    ASS1 Promotes Atherosclerotic Inflammation Through the NLRP3/IL-33/ST2 Axis in Ox-LDL–Induced Foam Cells

    by Shaoyu Wu, Feihuang Han, Zheng Qiao, Sheng Yuan, Xiaohui Bian, Bin Zhang, Kefei Dou, Dunliang Ma

    Background: Atherosclerosis is a chronic inflammatory disease characterized by lipid-driven immune dysregulation. Argininosuccinate synthase 1 (ASS1) has been implicated in macrophage inflammation, yet its precise mechanistic role in foam cell-mediated vascular injury during atherosclerosis remains unclear. This study investigates whether ASS1 promotes disease progression via the NLRP3/IL-33/ST2 axis. Methods: An in vitro foam cell model was established using phorbol 12-myristate 13-acetate (PMA)-differentiated U937 macrophages treated with oxidized low-density lipoprotein (ox-LDL). The role of ASS1 was assessed via knockdown (si-ASS1) and overexpression (ASS1 overexpression) plasmids. Co-culture systems with human umbilical vein endothelial cells (HUVECs) and human aortic vascular smooth muscle cells (HAVSMCs) were used to evaluate endothelial apoptosis and VSMC proliferation/migration. In vivo, atherosclerosis was induced in apolipoprotein E‑deficient (ApoE)-deficient mice via a 12-week high-fat diet, and ASS1 expression was modulated using AAV9 vectors. Molecular analyses included ROS detection, enzyme-linked immunosorbent assay (ELISA), qPCR, western blot, and immunofluorescence. Plaque burden was assessed via Oil Red O staining. Results: Ox-LDL treatment significantly upregulated ASS1 expression in U937-derived foam cells. ASS1 overexpression enhanced intracellular ROS production, NLRP3 inflammasome activation, STAT3 phosphorylation, and IL-33 secretion. These effects were reversed by ASS1 knockdown. Rescue experiments demonstrated that STAT3 is required for ASS1-mediated NLRP3 activation and IL-33 upregulation. ASS1 altered IL-33 receptor ST2 signaling by increasing the soluble decoy isoform (sST2) and decreasing the membrane-bound signaling isoform (ST2L). In co-culture, ASS1-overexpressing foam cells promoted HUVEC apoptosis (via mitochondrial pathway) and HAVSMC proliferation, migration, and dedifferentiation. NLRP3 overexpression alone mimicked the pro-inflammatory effects of ASS1 and reversed the anti-inflammatory effects of ASS1 knockdown. In vivo, ASS1 knockdown in ApoE-/- mice reduced plaque lipid deposition, serum levels of IL-33 and IL-1β, and vascular expression of NLRP3 and p-STAT3, while ASS1 overexpression exacerbated these parameters. Conclusions: ASS1 drives atherosclerosis by activating the STAT3/NLRP3 inflammasome axis, shifting the IL-33/ST2 balance toward a pro-inflammatory state, and amplifying foam cell–mediated endothelial injury and smooth muscle cell dysfunction. Targeting ASS1 may offer a novel therapeutic strategy for inflammatory vascular disease.

  • Open Access

    Association between triglyceride glucose-body roundness index and incidence diabetes mellitus: a cohort study

    by Xingjie Huang, Feihuang Han, Jiquan Xiao, Qiheng Wan, Dunliang Ma, Nan Chen, Song Wen


  • Open Access

    Bilateral Approach With Single Guiding Catheter for Negotiation in Retrograde PCI

    by Feihuang Han, Dunliang Ma, Qiheng Wan, Shaoyu Wu, Feng Wang, Yuqing Huang, Song Wen, Lam Lap Tin, Zehan Huang, Bin Zhang

  • Bailout Retrieval of an Entrapped, Fractured, and Undeflatable Stent Balloon in the Left Main Coronary Artery: A Salvage Procedure During Cardiac Arrest

    by Feihuang Han, Dunliang Ma, Qiheng Wan, Yuqing Huang, Zehan Huang, Feng Wang, Song Wen, Bin Zhang, Sue Liu

    Background: Balloon catheter fracture is a rare PCI complication that may trigger catastrophic coronary entrapment. This represents the first reported cardiac arrest during percutaneous retrieval of an entrapped, fractured stent balloon in an unprotected left main artery. Case Summary: A 72‐year‐old male developed sudden hemodynamic collapse during balloon extraction due to a shaft fracture. Under ongoing CPR with IABP/intubation support, modified balloon anchoring via high‐pressure secondary inflation in 7 F extension catheter enabled en bloc retrieval, with cardiac surgical/ECMO teams preemptively mobilized. Coronary flow was immediately restored, permitting extubation within 1 h and discharge after 5 days without sequelae. Conclusion: Salvage of such events mandates operator agility for bailout adaptation and on‐site availability of a multidisciplinary rescue team.


  • A Retrospective Cohort Study on Long-Term Outcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion

    by Feihuang Han, Dunliang Ma, Song Wen, Qiheng Wan, Yuqing Huang, Feng Wang, Zehan Huang, Bin Zhang

    Background Chronic total occlusion (CTO) affects 15–25% of patients undergoing coronary angiography, and successful percutaneous coronary intervention (PCI) can improve ischemia, angina symptoms, and overall quality of life. However, CTO-PCI is a complex procedure with higher risks of acute thrombosis, restenosis, and long-term thrombosis due to factors such as longer lesion length, calcification, and the need for more stents. Dual antiplatelet therapy (DAPT) is essential after PCI, but the optimal regimen for CTO, particularly in patients with chronic coronary syndrome, remains under debate. Although more potent P2Y12 inhibitors such as ticagrelor may offer benefits in some cases, recent studies have shown mixed results. Objective This study aimed to assess the effect of potent DAPT on long-term outcomes in patients with CTO undergoing retrograde PCI. Method We conducted a retrospective analysis of 836 consecutive patients who underwent elective retrograde CTO-PCI at a single center between January 2011 and April 2023. We compared patient and lesion characteristics, procedural details and results, and long-term outcomes between patients who received ticagrelor and those who received clopidogrel after retrograde CTO-PCI. Result Clinical follow-up was available in 767 (91.2%) patients, with a median follow-up of 1041 days (range 531–1511). The risk of major adverse cardiovascular events was significantly lower in patients receiving ticagrelor than in those receiving clopidogrel (8.8% vs. 18.5%, p = 0.005), primarily due to reductions in all-cause mortality (1.9% vs. 8.1%, p = 0.009) and cardiac death (0.6% vs. 5.8%, p = 0.012). Conclusion DAPT with ticagrelor may represent a safe and efficient management strategy for patients undergoing retrograde CTO-PCI.